Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRACR2A | Q9BSW2 | 15/20 | 0.43 |
| ▸ | ORAI1 | Q96D31 | 3/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30677012 | 0.84 | CRACR2A (0.55) | CRACR2AORAI1PTGS2 | |
| SCHEMBL31546295 | 0.83 | CRACR2A (0.43) | CRACR2AORAI1 | |
| SCHEMBL30677159 | 0.80 | MAPK14 (0.44) | ORAI1MAPK14 | |
| SCHEMBL30677064 | 0.75 | CRACR2A (0.39) | CRACR2AORAI1 | |
| SCHEMBL30785286 | 0.74 | CRACR2A (0.56) | CRACR2AORAI1PTGS2 | |
| SCHEMBL30677139 | 0.73 | CRACR2A (0.44) | CRACR2AORAI1PTGS2 | |
| SCHEMBL31625145 | 0.71 | KLKB1 (0.48) | ORAI1MAPK14PTGS2 | |
| SCHEMBL30785292 | 0.71 | CRACR2A (0.53) | CRACR2AORAI1PTGS2 | |
| SCHEMBL31625143 | 0.71 | KLKB1 (0.48) | ORAI1MAPK14PTGS2 | |
| SCHEMBL1880912 | 0.69 | CRACR2A (0.56) | CRACR2AORAI1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4543890-A1 | USP1 INHIBITORS AND USES THEREOF | Forma Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-119731178-A | USP1 inhibitors and uses thereof | 福马治疗有限公司 | 2025-03-28 | — | — | CN | disclosed |
| WO-2023250084-A1 | USP1 INHIBITORS AND USES THEREOF | FORMA THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |